Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sometimes triggers acute encephalopathy as a serious neurological complication in children. We previously reported the clinico-radiological findings of SARS-CoV-2-associated encephalopathy. The advent of the SARS-CoV-2 omicron variant led to a marked increase in pediatric patients with coronavirus disease 2019 (COVID-19); however, epidemiological changes with acute encephalopathy according to the emergence of SARS-CoV-2 have not yet been documented. Therefore, the present study investigated epidemiological differences in SARS-CoV-2-associated encephalopathy during the BA.1/BA.2 and BA.5 predominant periods and also between SARS-CoV-2-associated and non-SARS-CoV-2-associated encephalopathy. We conducted a nationwide survey of SARS-CoV-2-associated encephalopathy in Japanese children between June and November 2022. We compared the present results during the BA.5 predominant period and previous findings during the BA.1/BA.2 predominant period. We also compared the clinico-radiological syndromes of encephalopathy between SARS-CoV-2-associated and non-SARS-CoV-2-associated encephalopathy. Although many patients with SARS-CoV-2-associated encephalopathy in the BA.5 predominant period had seizures as their initial symptoms, no significant differences were observed in the clinical features. Patients with SARS-CoV-2-associated encephalopathy had worse outcomes than those with non-SARS-CoV-2-associated encephalopathy (p-value = 0.003). Among 103 patients with SARS-CoV-2-associated encephalopathy, 14 (13.6%) had severe types of acute encephalopathy, namely, encephalopathy with acute fulminant cerebral edema (AFCE) and hemorrhagic shock and encephalopathy syndrome (HSES). Also, 28 (27.2%) patients with SARS-CoV-2-associated encephalopathy had poor outcome: severe neurological sequelae or death. Ninety-five patients (92.2%) were not vaccinated against SARS-CoV-2. In SARS-CoV-2-associated encephalopathy, high percentages of AFCE and HSES can result in poor outcomes.
Background: Cardiac arrhythmias are sometimes encountered in patients with hereditary myopathies and muscular dystrophies. Description of arrhythmias in myopathies and muscular dystrophies is very important, because arrhythmias have a strong impact on the outcomes for these patients and are potentially treatable. Case presentation: A girl with severe congenital RYR1-related myopathy exhibited atrial tachycardia and sinus node dysfunction during infancy. She was born after uncomplicated caesarian delivery. She showed no breathing, complete ophthalmoplegia, complete bulbar paralysis, complete facial muscle paralysis, and extreme floppiness. At 5 months old, she developed persistent tachycardia around 200–210 beats per minutes. Holter monitoring revealed ectopic atrial tachycardia during tachyarrhythmia and occasional sinus pauses with junctional escape beats. Propranolol effectively alleviated tachyarrhythmia but was discontinued due to increased frequency and duration of the sinus pauses that led to bradyarrhythmia. There was no evidence of structural heart diseases or heart failure. The arrhythmia gradually resolved spontaneously and at 11 months old, she showed complete sinus rhythm. Conclusions: Although supraventricular arrhythmia is sometimes encountered in congenital myopathies, this is the first report of cardiac arrhythmia requiring drug intervention in RYR1-associated myopathy.
Objective: Transitioning patients with childhood‐onset epilepsy to adult care is often challenging, particularly for those with complex medical or social backgrounds. This study aimed to identify key factors associated with a successful transfer to inform strategies that support continuity during this vulnerable period. Methods: A retrospective cohort study was conducted using medical records from the National Center for Child Health and Development, a tertiary pediatric hospital in Tokyo, Japan. Patients with epilepsy aged 18 years or older who had regular outpatient visits between January 1 and March 31, 2018, were enrolled and followed until June 30, 2022. Results: At the start of the study, 232 patients were identified, 225 patients were evaluated, and 186 (82.7%) were successfully transferred to adult care during the study period. The median age at transfer to adult care was 23 years. Successful transfer was significantly associated with epilepsy etiology, the presence of comorbidities, and support from transition services. Patients requiring assistance with daily living were more likely to transfer to neurologic non‐specialty care facilities, such as psychiatric clinics or home‐based care providers. Significance: Identifying factors associated with transition outcomes can help healthcare providers anticipate potential barriers and facilitate smoother transitions for patients with childhood‐onset epilepsy who require ongoing adult care. Plain Language Summary: We studied how young people with epilepsy move from children's hospitals to adult healthcare. Most patients successfully transitioned to adult care. During the observation period, transfer was more likely among those with different types of epilepsy and those who received support from transition services. Patients who were also seeing other medical departments tended to transfer less often. Our study highlights factors that may help plan better support for patients with childhood‐onset epilepsy.